Teduglutide (TED) is widely used in patients with short-bowel-syndrome-associated intestinal failure (SBS-IF) to enhance intestinal adaptation and reduce the need for parenteral support (PS). There are limited data on the effects of discontinuing TED. In this study, we describe the changes in parenteral nutrition (PN) requirements and body mass index (BMI) in a 9-year follow-up of patients receiving home parenteral nutrition after discontinuation of the TED treatment. We performed a retrospective analysis of changes in weekly PN orders and BMI in all patients with PN-dependent SBS from two Polish home parenteral nutrition (HPN) centers who received teduglutide between 2009 and 2013 and still required HPN 9 years after discontinuation of the TED treatment. Data included in the analysis were collected prospectively at mandatory visits to the HPN centers at 12, 24, 60, 84, and 108 months after drug discontinuation and compared with values before and after TED treatment. Weekly PN volume values varied significantly between all of the above time points from baseline to 9 years after TED discontinuation (χ2 = 34.860, p < 0.001). After an initial increase within the first year after treatment discontinuation (not statistically significant), the PN volume requirements remained stable for 4 years and increased 5–9 years after treatment discontinuation. The rate of patients requiring an increase in PN volume was 84.62% at 60 and 84 months and 92.30% at 108 months. At 9 years after cessation of the TED treatment, 53.85% of the study group required a 21.21% increase in PN volume compared with values before treatment. The need for PN volume in patients with PN-dependent SBS who discontinued the TED treatment increased within the first year and 4–5 years after treatment cessation, and in some cases might even exceed pretreatment values after 9 years.
Background: Chronic intestinal failure (CIF), most commonly caused by short bowel syndrome (SBS), necessitates complex care. This review explores the gut microbiota’s role in intestinal adaptation in SBS, examining its potential as both a biomarker and therapeutic target. SBS results from extensive small bowel resection, leading to malabsorption and dependence on parenteral nutrition (PN). Post-resection, the gut microbiota undergoes significant alterations. While the small bowel microbiome typically comprises Streptococcus, Veillonella, and others, SBS patients often exhibit increased Gram-negative Proteobacteria. Dysbiosis is linked to adverse outcomes like liver disease and impaired growth, but beneficial effects such as energy salvage also occur. Intestinal adaptation, a process of increasing absorptive surface area in the remaining bowel, involves acute, remodeling, and maintenance phases. Preservation of ileum and stimulation with the oral diet are crucial. Biomarkers are needed to predict success, with gut microbiota composition emerging as a promising non-invasive option. The precise mechanisms driving adaptation remain incompletely understood. Conclusions: GLP-1 and GLP-2 analogues show promise in enhancing adaptation and reducing PN dependence. Surgical rehabilitation aims to maximize intestinal absorptive capacity, while transplantation remains a last resort due to high complication risks. Further research is needed to fully elucidate the microbiota’s role and harness its potential in managing SBS.
Background: The prognostic nutritional index (PNI) is an inexpensive marker derived from serum albumin and peripheral lymphocyte count. Although low PNI has been associated with adverse surgical outcomes, its incremental value beyond basic clinical variables and the stability of commonly used thresholds remain uncertain in heterogeneous colorectal surgical populations. We evaluated the association between preoperative PNI and postoperative complications and examined whether adding PNI improved a basic clinical model. Methods: This retrospective single-center cohort included 205 consecutive adults undergoing colorectal surgery between January 2024 and March 2026. PNI was calculated as albumin (g/L) + 5 × lymphocyte count (109/L). PNI was modeled primarily as a continuous predictor; PNI < 45 was examined secondarily. ROC analysis, multivariable logistic regression, nested-model comparison, calibration assessment, bootstrap internal validation, complete-case sensitivity analysis, and exploratory subgroup analyses were performed. Results: Fifty-six patients (27.3%) had PNI < 45. Postoperative complications occurred in 67 patients (32.7%) overall and were more frequent with PNI < 45 (51.8% vs. 25.5%; RR 2.03, 95% CI 1.40–2.95; OR 3.14, 95% CI 1.65–5.95; Fisher p < 0.001). PNI alone showed modest discrimination (AUC 0.659); the Youden cutoff was 45.45 (sensitivity 50.7%, specificity 78.3%). In the complete-case multivariable model (n = 191), each 5-point decrease in PNI was associated with higher odds of complications (OR 1.52, 95% CI 1.22–1.90; p < 0.001). Adding continuous PNI to age, BMI, and operative approach increased AUC from 0.663 to 0.711 and improved model fit (likelihood-ratio χ2 = 15.89, p < 0.001). Bootstrap resampling showed substantial cutoff variability (95% percentile interval 32.05–52.00). Conclusions: Lower preoperative PNI was associated with postoperative complications and added discriminatory information to a basic clinical model. However, its stand-alone discrimination was modest, the data-derived cutoff was unstable on bootstrap resampling, and residual confounding and clinical heterogeneity limit causal or treatment-directed interpretation. PNI should therefore be considered a risk marker rather than a stand-alone decision rule. Prospective interventional studies in well-defined patient groups are needed to determine whether PNI-guided nutritional optimization improves outcomes.